TECENTRIQ provides an extra first-line treatment option for patients with metastatic NSCLC and high PD-L1 expression.2–6 Compared with platinum-based chemotherapy, it can give patients the chance of:
Physicians should consider the delayed onset of TECENTRIQ effect before initiating first-line treatment as monotherapy in patients with NSCLC.3–6
-
IMpower110 study design
- IMpower110 was a randomised, open-label, multicentre, phase III trial which assessed the efficacy and safety of TECENTRIQ compared with platinum-based chemotherapy in patients with metastatic NSCLC whose disease was
PD-L1 positive and was not EGFR-mutant or ALK-positive, and who had not previously received chemotherapy1,9
Primary endpoint1
- OS in patients without EGFR mutations or ALK translocations
- OS was tested hierarchically:
- TC3 or IC3 population (PD-L1 expression on ≥50% of tumour cells or ≥10% of tumour-infiltrating immune cells)
- TC2/3 or IC2/3 population (PD-L1 expression on ≥5% of tumour cells or tumour-infiltrating immune cells)
- TC1/2/3 or IC1/2/3 population (PD-L1 expression on ≥1% of tumour cells or tumour-infiltrating immune cells)
Key secondary endpoints1
- Investigator-assessed PFS according to RECIST, v1.1
- ORR
- DoR
- OS and investigator-assessed PFS according to RECIST, version 1.1 in prespecified subgroups with respect to PD-L1 expression (defined by the SP263 immunohistochemical assay) and blood-based tumour mutational burden
- Safety (assessed in all treated patients regardless of PD-L1 expression, EGFR or ALK status)
- IMpower110 was a randomised, open-label, multicentre, phase III trial which assessed the efficacy and safety of TECENTRIQ compared with platinum-based chemotherapy in patients with metastatic NSCLC whose disease was
-
Baseline characteristics
- Baseline characteristics were generally balanced between treatment groups1
*The TC1/2/3 or IC1/2/3 population was defined as patients with PD-L1 expression on ≥1% of tumour cells or tumour-infiltrating immune cells. The TC3 or IC3 population was defined as patients with PD-L1 expression on ≥50% of tumour cells or ≥10% of tumour-infiltrating immune cells. Both population are comprised of patients who did not have EGFR-mutant or ALK-positive disease.
†Race was reported by the patients. One patient in the TECENTRIQ TC1/2/3 or IC1/2/3 population was categorised as having multiple races (not shown).
Adapted from Herbst1
Median OS – primary endpoint1
15.7 months’ median follow-up (range 0–35 months).
Adapted from Herbst1
Physicians should consider the delayed onset of TECENTRIQ effect before initiating first-line treatment as monotherapy in patients with NSCLC.3–6
45.5% of patients treated with TECENTRIQ lived for at least 2 years7
15.7 months’ median follow-up (range 0–35 months).
Adapted from Herbst1 and Data on File M-GB-000033647
- The 18-month OS rate was 54.6% (95% CI: 43.4–65.7) with TECENTRIQ vs 27.3% (95% CI: 15.5–39.1) with chemotherapy7
- Treatment with TECENTRIQ could continue after disease progression in patients who had a continued clinical benefit1
-
PFS was 8.1 months with TECENTRIQ compared with 5.0 months with platinum-based chemotherapy¹
Median PFS – secondary endpoint1
15.7 months’ median follow-up (range 0–35 months).
Adapted from Herbst1
36.9% of patients treated with TECENTRIQ lived for at least 1 year without disease progression1
Landmark PFS1
15.7 months’ median follow-up (range 0–35 months).
Adapted from Herbst1
-
TECENTRIQ achieved an objective response in 38.3% of patients vs 28.6% with platinum-based chemotherapy¹
ORR and DoR – secondary endpoints1
15.7 months’ median follow-up (range 0–35 months).
Adapted from Herbst1- At data cut-off, responses were ongoing in 68.3% of patients treated with TECENTRIQ vs 35.7% of patients with chemotherapy1
-
Patients’ overall HRQoL was sustained through to week 57 with TECENTRIQ and declined from week 42 with platinum-based chemotherapy⁸
- Patients’ overall HRQoL remained clinically stable through to week 57 of treatment with TECENTRIQ8
- Patients treated with chemotherapy experienced a clinically meaningful decline in overall HRQoL from week 42 onwards8
Mean change from baseline on the QLQ-C30 Global Health Status Scale – exploratory endpoint8
Adapted from De Marinis8
TECENTRIQ is a cost-effective treatment option for the NHS2
ALK, anaplastic lymphoma kinase; AUC, area under the curve; CI, confidence interval; DoR, duration of response; ECOG, European Cooperative Oncology Group; EGFR, epidermal growth factor receptor; HR, hazard ratio; HRQoL, health-related quality of life; NE, not estimable; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PD-L1, programmed death ligand 1; PFS, progression-free survival; PS, performance status; q3w, every 3 weeks; RECIST, Response Evaluation Criteria in Solid Tumours.
References:
- Herbst RS et al. N Engl J Med 2020; 383(14): 1328–1339.
- NICE. Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (TA705). June 2021.
- TECENTRIQ 840 mg GB Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/10697/smpc accessed June 2021.
- TECENTRIQ 1200 mg GB Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/8442/smpc accessed June 2021.
- TECENTRIQ 840 mg NI Summary of Product Characteristics. Available at: https://www.emcmedicines.com/en-gb/northernireland/medicine?id=613af771-ca30-4888-a5a2-c4bbc6db7a72 accessed June 2021.
- TECENTRIQ 1200 mg NI Summary of Product Characteristics. Available at: https://www.emcmedicines.com/en-gb/northernireland/medicine?id=473d233f-1423-422f-bf6b-14e056ec47b9&submissionId=1c477cd5-30d1-4261-850e-64136952a044 accessed June 2021.
- Roche. Data on File M-GB-00003364. April 2021.
- De Marinis F et al. Presented at the ASCO Annual Meeting; May 29–31, 2020. Poster #360.
- Spigel DR et al. Presented at the ESMO Congress, Barcelona, Spain; 27 September to 1 October, 2019. Oral presentation.
M-GB-00004098.
Date of preparation: June 2021.